Literature DB >> 9337772

Manual-guided psychosocial treatment. A new virtual requirement for pharmacotherapy trials?

K M Carroll1.   

Abstract

The conduct of randomized clinical trials to evaluate the efficacy of pharmacotherapies for mental disorders is guided by research standards (at a high level of rigor) that govern most design elements, including randomization of subjects, use of placebo controls, formulation and dosage of the therapeutic agent, and monitoring of serum levels. In contrast, no such widely accepted guidelines are recognized for standardization of an essential, if unacknowledged, element of all such studies: the concomitant provision of at least a minimal form of psychosocial treatment. Standardized provision of psychosocial treatments in pharmacotherapy trials will foster replicability of findings and address several common problems (e.g., attrition, medication noncompliance, reduction of error variance, and ethical issues associated with placebo controls). Careful selection and standardization of the psychosocial context in which medications are delivered will improve the validity, precision, and power of pharmacotherapy efficacy research, and should be considered a virtual requirement in research design.

Entities:  

Keywords:  Biomedical and Behavioral Research; Mental Health Therapies

Mesh:

Substances:

Year:  1997        PMID: 9337772     DOI: 10.1001/archpsyc.1997.01830220041007

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  23 in total

Review 1.  Choosing a behavioral therapy platform for pharmacotherapy of substance users.

Authors:  Kathleen M Carroll; Thomas R Kosten; Bruce J Rounsaville
Journal:  Drug Alcohol Depend       Date:  2004-08-16       Impact factor: 4.492

2.  The κ-opioid receptor gene as a predictor of response in a cocaine vaccine clinical trial.

Authors:  David A Nielsen; Sara C Hamon; Thomas R Kosten
Journal:  Psychiatr Genet       Date:  2013-12       Impact factor: 2.458

Review 3.  Recent advances in the psychotherapy of addictive disorders.

Authors:  Kathleen M Carroll
Journal:  Curr Psychiatry Rep       Date:  2005-10       Impact factor: 5.285

4.  A perfect platform: combining contingency management with medications for drug abuse.

Authors:  Kathleen M Carroll; Bruce J Rounsaville
Journal:  Am J Drug Alcohol Abuse       Date:  2007       Impact factor: 3.829

5.  Game playbooks: tools to guide multidisciplinary teams in developing videogame-based behavior change interventions.

Authors:  Lindsay R Duncan; Kimberly D Hieftje; Sabrina Culyba; Lynn E Fiellin
Journal:  Transl Behav Med       Date:  2014-03       Impact factor: 3.046

Review 6.  Computer-assisted therapy in psychiatry: be brave-it's a new world.

Authors:  Kathleen M Carroll; Bruce J Rounsaville
Journal:  Curr Psychiatry Rep       Date:  2010-10       Impact factor: 5.285

7.  Effects of major depressive disorder and attention-deficit/hyperactivity disorder on the outcome of treatment for cocaine dependence.

Authors:  Frances R Levin; Adam Bisaga; Wilfrid Raby; Efrat Aharonovich; Eric Rubin; John Mariani; Daniel J Brooks; Fatima Garawi; Edward V Nunes
Journal:  J Subst Abuse Treat       Date:  2007-06-15

8.  An exploratory evaluation of Take Control: A novel computer-delivered behavioral platform for placebo-controlled pharmacotherapy trials for alcohol use disorder.

Authors:  Eric G Devine; Megan L Ryan; Daniel E Falk; Joanne B Fertig; Raye Z Litten
Journal:  Contemp Clin Trials       Date:  2016-08-10       Impact factor: 2.226

9.  DBH gene as predictor of response in a cocaine vaccine clinical trial.

Authors:  Thomas R Kosten; Coreen B Domingo; Sara C Hamon; David A Nielsen
Journal:  Neurosci Lett       Date:  2013-02-28       Impact factor: 3.046

10.  Pharmacogenetic randomized trial for cocaine abuse: disulfiram and dopamine β-hydroxylase.

Authors:  Thomas R Kosten; Guiying Wu; Wen Huang; Mark J Harding; Sara C Hamon; Jaakko Lappalainen; David A Nielsen
Journal:  Biol Psychiatry       Date:  2012-08-18       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.